OLD Mission Capital LLC Buys Shares of 6,151 Gilead Sciences (GILD)

OLD Mission Capital LLC bought a new stake in shares of Gilead Sciences (NASDAQ:GILD) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 6,151 shares of the biopharmaceutical company’s stock, valued at approximately $441,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Welch Investments LLC bought a new position in shares of Gilead Sciences in the 3rd quarter worth approximately $108,000. Wealthcare Advisory Partners LLC bought a new position in shares of Gilead Sciences in the 3rd quarter worth approximately $133,000. Horan Capital Advisors LLC. bought a new position in shares of Gilead Sciences in the 3rd quarter worth approximately $144,000. Hanson & Doremus Investment Management lifted its stake in shares of Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 1,613 shares during the period. Finally, Rowland & Co. Investment Counsel ADV bought a new position in shares of Gilead Sciences in the 2nd quarter worth approximately $153,000. Institutional investors and hedge funds own 78.35% of the company’s stock.

How to Become a New Pot Stock Millionaire

In related news, Director John Francis Cogan sold 5,833 shares of the firm’s stock in a transaction on Friday, April 13th. The shares were sold at an average price of $75.56, for a total value of $440,741.48. Following the completion of the transaction, the director now directly owns 58,452 shares of the company’s stock, valued at $4,416,633.12. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Robin L. Washington sold 5,000 shares of the firm’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total transaction of $401,550.00. Following the completion of the transaction, the chief financial officer now directly owns 23,749 shares of the company’s stock, valued at $1,907,282.19. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 308,600 shares of company stock valued at $24,328,226. Insiders own 1.30% of the company’s stock.

Shares of GILD opened at $74.44 on Friday. The company has a quick ratio of 2.67, a current ratio of 2.74 and a debt-to-equity ratio of 1.53. Gilead Sciences has a 1 year low of $63.76 and a 1 year high of $89.54. The company has a market cap of $98,401.56, a price-to-earnings ratio of 8.70, a P/E/G ratio of -1.74 and a beta of 1.19.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The business had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. During the same period last year, the firm posted $2.70 EPS. The company’s revenue was down 18.7% on a year-over-year basis. analysts forecast that Gilead Sciences will post 6.19 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 29th. Shareholders of record on Friday, March 16th were issued a dividend of $0.57 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a yield of 3.06%. The ex-dividend date was Thursday, March 15th. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.

GILD has been the topic of several recent research reports. Oppenheimer reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, December 21st. Zacks Investment Research cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. BMO Capital Markets reiterated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, January 3rd. Credit Suisse Group set a $80.00 target price on shares of Gilead Sciences and gave the stock a “hold” rating in a research note on Wednesday, January 3rd. Finally, BidaskClub cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $88.65.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://ledgergazette.com/2018/04/20/old-mission-capital-llc-buys-shares-of-6151-gilead-sciences-gild.html.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply